

### 29 September 2022

## **ASX Announcement**

# **Date of AGM & Closing Date for Director Nominations**

MELBOURNE Australia, 29 September 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Thursday, 17 November 2022.

An item of business at the AGM will be the re-election of Directors. In accordance with clause 13.3 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Thursday, 6 October 2022.

Any nominations must be received by the Company in writing by no later than 5:00 pm (Melbourne time) on Thursday, 6 October 2022.

### Approved for release to the ASX by:

Dr Paul MacLeman Executive Chairman Isla Pharmaceuticals info@islandpharmaceuticals.com

For further information, please contact:

Investors:
Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

**Media:** Juliana Roadley IR Department

Mobile: +61 414 889 863

<u>juliana.roadley@irdepartment.com.au</u>

#### **About Island Pharmaceuticals**

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, following a successful Phase III trial, and certain other criteria are met, Isla may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV)would permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.



Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit <u>www.islandpharmaceuticals.com</u> for more on Island.